Background: Alzheimer's disease (AD) is associated with cerebral slowing on electroencephalography (EEG), or a shift in oscillatory power from higher to lower frequencies. This change can be captured as the spectral power ratio (SPR) of alpha and beta over delta and theta: (α+β)/(δ+θ). Prior studies have shown that compared to cognitively unimpaired older adults, the SPR was lower in persons with a clinical diagnosis of dementia due to probable AD and those with a biomarker-confirmed diagnosis of amnestic mild cognitive impairment (aMCI) due to AD, and a lower SPR was associated with worse executive functions scores.
View Article and Find Full Text PDFThe goal of the TEDDY (The Environmental Determinants of Diabetes in the Young) study is to elucidate factors leading to the initiation of islet autoimmunity (first primary outcome) and those related to progression to type 1 diabetes mellitus (T1DM; second primary outcome). This Review outlines the key findings so far, particularly related to the first primary outcome. The background, history and organization of the study are discussed.
View Article and Find Full Text PDFStable isotope labelling by amino acids in cell culture (SILAC) is an established technique used in quantitative mass spectrometry (MS)-based proteomics. SILAC is also used to generate stable isotope labelled (SIL) antibodies for internal standards (IS) used in LC-MS/MS bioassays to improve quantitative robustness.Total antibody (TAb) is measured to evaluate pharmacokinetics (PK) of antibody drug conjugate (ADC) candidates measured by either ligand binding (LBA) or LC-MS/MS.
View Article and Find Full Text PDFBackground: Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies.
Methods: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, randomised controlled trial that enrolled adults with newly diagnosed active Crohn's disease (Harvey-Bradshaw Index ≥7, either elevated C-reactive protein or faecal calprotectin or both, and endoscopic evidence of active inflammation).